- Home
- AENT vs MNPR Comparison
AENT vs MNPR Comparison
Compare AENT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- MNPR
- Stock Information
- Founded
- AENT 1990
- MNPR 2014
- Country
- AENT United States
- MNPR United States
- Employees
- AENT N/A
- MNPR N/A
- Industry
- AENT Durable Goods
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- AENT Consumer Discretionary
- MNPR Health Care
- Exchange
- AENT Nasdaq
- MNPR Nasdaq
- Market Cap
- AENT 290.3M
- MNPR 250.0M
- IPO Year
- AENT N/A
- MNPR 2019
- Fundamental
- Price
- AENT $4.18
- MNPR $40.25
- Analyst Decision
- AENT
- MNPR Strong Buy
- Analyst Count
- AENT 0
- MNPR 4
- Target Price
- AENT N/A
- MNPR $43.00
- AVG Volume (30 Days)
- AENT 92.0K
- MNPR 71.2K
- Earning Date
- AENT 02-13-2025
- MNPR 03-27-2025
- Dividend Yield
- AENT N/A
- MNPR N/A
- EPS Growth
- AENT N/A
- MNPR N/A
- EPS
- AENT 0.13
- MNPR N/A
- Revenue
- AENT $1,070,804,000.00
- MNPR N/A
- Revenue This Year
- AENT $4.77
- MNPR N/A
- Revenue Next Year
- AENT N/A
- MNPR N/A
- P/E Ratio
- AENT $32.31
- MNPR N/A
- Revenue Growth
- AENT N/A
- MNPR N/A
- 52 Week Low
- AENT $1.10
- MNPR $1.72
- 52 Week High
- AENT $11.57
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- AENT 37.49
- MNPR 49.34
- Support Level
- AENT $3.17
- MNPR $38.80
- Resistance Level
- AENT $5.29
- MNPR $45.60
- Average True Range (ATR)
- AENT 0.66
- MNPR 5.19
- MACD
- AENT -0.10
- MNPR -1.50
- Stochastic Oscillator
- AENT 29.56
- MNPR 9.37
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.